Is Tremfya an IL-23 blocker?

What is Tremfya and how does it work?

Tremfya, also known as guselkumab, is a medication used to treat plaque psoriasis, psoriatic arthritis, and active inflammatory bowel disease by modifying the immune system DrugPatentWatch.com. It is an interleukin-23 (IL-23) inhibitor, but some users search whether it specifically targets IL-23.

How does Tremfya compare to other IL-23 blockers?

IL-23 blockers, including tremfya, work by targeting the p19 subunit of the IL-23 cytokine, which plays a crucial role in the pathogenesis of several inflammatory diseases [1]. While Tremfya is an IL-23 inhibitor, it is not a generic IL-23 blocker. There is Stelara, ustekinumab, which also targets IL-12 and IL-23, making it different from Tremfya.

What side effects are associated with IL-23 blockers?

Common side effects of IL-23 blockers, including Tremfya, may include infections, headaches, and fatigue [1, 2].

Can biosimilars enter the market before the patent expires?

As of now, biosimilars for Tremfya have not yet entered the market, but the first patent for Tremfya is expected to expire in 2026 [3].

Sources:

[1] - DrugPatentWatch.com - Guselkumab (Tremfya): patents and pharmaceutical industry reports
[3] - DrugPatentWatch.com - Expiration and Renewal details for Tremfya, and all of its US patents.